WO2004078950A3 - METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS - Google Patents

METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS Download PDF

Info

Publication number
WO2004078950A3
WO2004078950A3 PCT/US2004/007053 US2004007053W WO2004078950A3 WO 2004078950 A3 WO2004078950 A3 WO 2004078950A3 US 2004007053 W US2004007053 W US 2004007053W WO 2004078950 A3 WO2004078950 A3 WO 2004078950A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
gene expression
arrays
mediated inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/007053
Other languages
French (fr)
Other versions
WO2004078950A2 (en
Inventor
Jen-Tsan Chi
Howard Y Chang
Patrick Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP04717516A priority Critical patent/EP1604012A2/en
Publication of WO2004078950A2 publication Critical patent/WO2004078950A2/en
Anticipated expiration legal-status Critical
Publication of WO2004078950A3 publication Critical patent/WO2004078950A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

RNAi arrays and methods for using the same are provided. The subject arrays are characterized by having two or more distinct RNAi agents. The arrays find use in methods where cells are contacted with the arrays and the activity of the RNAi agents is determined by evaluating the contacted cells. The subject arrays and methods find use in a variety of applications, such as high throughput loss of function genomic applications.
PCT/US2004/007053 2003-03-05 2004-03-04 METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS Ceased WO2004078950A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04717516A EP1604012A2 (en) 2003-03-05 2004-03-04 METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45237903P 2003-03-05 2003-03-05
US60/452,379 2003-03-05

Publications (2)

Publication Number Publication Date
WO2004078950A2 WO2004078950A2 (en) 2004-09-16
WO2004078950A3 true WO2004078950A3 (en) 2006-03-02

Family

ID=32962715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007053 Ceased WO2004078950A2 (en) 2003-03-05 2004-03-04 METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS

Country Status (3)

Country Link
US (1) US20050026286A1 (en)
EP (1) EP1604012A2 (en)
WO (1) WO2004078950A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5101288B2 (en) 2004-10-05 2012-12-19 カリフォルニア インスティテュート オブ テクノロジー Aptamer-regulated nucleic acids and uses thereof
US7723314B1 (en) 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
JP2010512155A (en) * 2006-12-13 2010-04-22 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング Transfection microarray
US8530436B2 (en) * 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
US20090107051A1 (en) * 2007-10-29 2009-04-30 Joseph Talpe Closure mechanism
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
BR112012024049A2 (en) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp rna interference on dermal and fibrotic indications
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
JP6037926B2 (en) * 2013-04-16 2016-12-07 三菱電機株式会社 Air conditioner
EP3077050B1 (en) 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102506169B1 (en) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
US11046952B2 (en) 2015-03-16 2021-06-29 The Broad Institute, Inc. Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
CN108135923B (en) 2015-07-06 2021-03-02 菲奥医药公司 Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
CN115135765A (en) 2019-11-08 2022-09-30 菲奥医药公司 Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy
WO2021138537A1 (en) 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
JP2024529025A (en) 2021-08-04 2024-08-01 フィオ ファーマシューティカルズ コーポレーション Chemically Modified Oligonucleotides
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US20020132788A1 (en) * 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US7125664B2 (en) * 2001-06-20 2006-10-24 Dahlia Minc-Golomb Method for identifying genes that are upstream regulators of other genes of interest
US20030032203A1 (en) * 2001-07-10 2003-02-13 Sabatini David M. Small molecule microarrays

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUI G. ET AL: "A DNA Vector-Based RNAi Technology to Suppress Gene Expression in Mammalian Cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 8, April 2002 (2002-04-01), pages 5515 - 5520, XP002964701 *
YU J. ET AL: "RNA Interference by Expression of Short-Interfering RNAs and Hairpin RNAs in Mammalian Cells", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 9, April 2002 (2002-04-01), pages 6047 - 6052, XP002259803 *

Also Published As

Publication number Publication date
EP1604012A2 (en) 2005-12-14
WO2004078950A2 (en) 2004-09-16
US20050026286A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2004078950A3 (en) METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2006137941A3 (en) Methods and compositions involving mirna and mirna inhibitor molecules
WO2005094370A3 (en) Oligonucleotide complex compositions and methods of use as gene alteration tools
WO2003062394A3 (en) Methods and compositions for rna interference
WO2006006948A3 (en) METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP1845160A4 (en) METHOD FOR AMPLIFYING A NUCLEOTIDE SEQUENCE
WO2006073601A3 (en) Methods and compositions for rna interference
HK1047109A1 (en) Rna interference pathway genes as tools for targeted genetic interference
EP1801213A3 (en) Polymerase
WO2009034927A1 (en) Cell culture instrument and cell culture method using the same
WO2001051663A3 (en) Integrated systems and methods for diversity generation and screening
WO2002101022A3 (en) Method for rapid amplification of dna
EP2168578A3 (en) Thiazole based inhibitors of atp-utilizing enyzmes
WO2005118008A3 (en) Compositions and articles containing a crosslinked polymer matrix and an immobilized active liquid, as well as methods of making and using the same
WO2004078946A3 (en) Rnai arrays and methods for using the same
WO2005081632A3 (en) Enzymes, cells and methods for site specific recombination at asymmetric sites
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2007024898A3 (en) Displays with integrated photovoltaic cells
WO2006060646A3 (en) Cell microarray for profiling of cellular phenotypes and gene function
WO2006070023A3 (en) Method for reversing multiple resistance in animal cells
WO2007008861A3 (en) Methods of transferring photovoltaic cells
GB2411281B (en) Storage device
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
EP2157182A3 (en) Modified short interfering RNA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004717516

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004717516

Country of ref document: EP